{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:34:14Z","timestamp":1782765254489,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.clinthera.2015.08.026","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T16:47:27Z","timestamp":1443372447000},"page":"2449-2457","source":"Crossref","is-referenced-by-count":5,"title":["Response and Adverse Effects of Nilotinib in Imatinib-resistant Chronic Myeloid Leukemia Patients: Data From a Developing Country"],"prefix":"10.1016","volume":"37","author":[{"given":"Shabneez","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Usman Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.08.026_bib1","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. Sep-Oct; 60:277\u2013300. PubMed PMID: 20610543. [Epub 2010\/07\/09. eng].","DOI":"10.3322\/caac.20073"},{"key":"10.1016\/j.clinthera.2015.08.026_bib2","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2015.08.026_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u05f3Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.08.026_bib4","first-page":"103","article-title":"Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response","volume":"55","author":"Usman","year":"2007","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.clinthera.2015.08.026_bib5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.08.026_bib6","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2015.08.026_bib7","doi-asserted-by":"crossref","unstructured":"Ottmann OG, Larson RA, Kantarjian HM, et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. Nov 9. PubMed PMID: 23138184. [Epub 2012\/11\/10. eng].","DOI":"10.1038\/leu.2012.324"},{"key":"10.1016\/j.clinthera.2015.08.026_bib8","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2015.08.026_bib9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2015.08.026_bib10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2015.08.026_bib11","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2015.08.026_bib12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2015.08.026_bib13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2015.08.026_bib14","unstructured":"Brien SO. NCCN clinical practice guidelines in Oncology. Chronic myeloid leukemia. In: Network NCC, editor. 2015, p. 11."},{"key":"10.1016\/j.clinthera.2015.08.026_bib15","doi-asserted-by":"crossref","unstructured":"Hehlmann R. How I treat CML blast crisis. Blood. Jul 26;120:737\u201347. PubMed PMID: 22653972. [Epub 2012\/06\/02. eng].","DOI":"10.1182\/blood-2012-03-380147"},{"key":"10.1016\/j.clinthera.2015.08.026_bib16","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.08.026_bib17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.08.026_bib18","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2015.08.026_bib19","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clinthera.2015.08.026_bib20","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2015.08.026_bib21","first-page":"1039","article-title":"Overview of chronic myeloid leukemia patients in akistan in the pre-imatanib era","volume":"10","author":"Usmani","year":"2009","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clinthera.2015.08.026_bib22","first-page":"469","article-title":"Presentating phases of chronic myeloid leukaemia","volume":"19","author":"Ahmed","year":"2009","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.clinthera.2015.08.026_bib23","first-page":"591","article-title":"Clinico-pathological features and outcomes in chronic phase chronic myeloid leukemia patients treated with hydroxyurea","volume":"10","author":"Irfan","year":"2009","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clinthera.2015.08.026_bib24","first-page":"336","article-title":"Clinico-pathologic features of chronic myeloid leukemia and risk stratification according to Sokal score","volume":"16","author":"Syed","year":"2006","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.clinthera.2015.08.026_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-012-1026-9","article-title":"Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed\/refractory Ph+ ALL: a 36-month analysis of a phase I and II study","volume":"95","author":"Usuki","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2015.08.026_bib26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2015.08.026_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2015.08.026_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","article-title":"A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed\/refractory Ph+ ALL","volume":"89","author":"Tojo","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2015.08.026_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2015.08.026_bib30","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2015.08.026_bib31","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2015.08.026_bib32","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2015.08.026_bib33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2015.08.026_bib34","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.08.026_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/JBM.S13067","article-title":"First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation","volume":"3","author":"Piccaluga","year":"2012","journal-title":"J Blood Med"},{"key":"10.1016\/j.clinthera.2015.08.026_bib36","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T01:21:47Z","timestamp":1567214507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815010991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0149291815010991"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.08.026","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}